Quantcast

Altos Therapeutics Receives Allowance For Issue Of United States Patent

February 12, 2014

LOS ALTOS, Calif., Feb. 12, 2014 /PRNewswire/ — Altos Therapeutics, LLC, was recently informed by the United States Patent and Trademark Office that its pending patent application covering Altos’ dopamine D2/D3 receptor antagonists for treating gastrointestinal diseases will be granted. The patent that issues will broadly and specifically cover the company’s drug candidates, their pharmaceutical compositions, and their use for treating a number of important gastrointestinal conditions in humans, such as gastroparesis.

The issuance in the United States will mark a significant milestone in establishing patent coverage for this important family of compounds throughout the world. These compounds are currently being developed to meet unmet clinical needs in conditions that are responsive to dopamine D2/D3 receptor antagonist activity. Patent protection in the US and other countries around the world is expected to extend through 2031 under present laws.

“This represents an important milestone in the development of our company,” stated Roger Whiting, Ph.D., President and CEO of Altos Therapeutics, “as extended intellectual property protection of our lead compounds will be a crucial aspect of our strategy to develop novel molecules for these disease states.”

About Dopamine D2/D3 Receptor Antagonists

D2/D3 receptor antagonists have a multimodal therapeutic effect including stimulating gastric motility, normalizing gastric rhythm via actions on the enteric nervous system and diminishing nausea and vomiting in a variety of gastrointestinal conditions.

About Gastroparesis

Gastroparesis is a chronic gastric motility disorder characterized by delayed gastric emptying. Symptoms include early satiety, postprandial fullness, nausea, vomiting, and abdominal discomfort. The current approved drug available in the United States for treating diabetic gastroparesis symptoms is metoclopramide, which suffers from a black box warning for tardive dyskinesia and is limited to acute use.

About Altos Therapeutics

Altos Therapeutics is committed to identifying and developing new medicines for gastrointestinal disorders in areas of high unmet medical need, including gastroparesis, functional dyspepsia, refractory gastroesophageal reflux disease (GERD), Parkinson’s disease, and refractory nausea. Altos Therapeutics is a private pharmaceutical company located in Los Altos, California.

Contact:
Roger Whiting, Co-founder, President and CEO

Office: 650.948.1200
Fax: 650.948.1221

Email: info@altostherapeutics.com

SOURCE Altos Therapeutics, LLC


Source: PR Newswire



comments powered by Disqus